StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report released on Monday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners lowered their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Price Performance

AWH opened at $0.91 on Monday. Aspira Women’s Health has a fifty-two week low of $0.74 and a fifty-two week high of $6.01. The company’s 50 day moving average price is $0.93 and its two-hundred day moving average price is $1.76. The firm has a market capitalization of $14.60 million, a price-to-earnings ratio of -0.63 and a beta of 1.47.

Aspira Women’s Health (NASDAQ:AWH) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same period in the prior year, the firm earned ($0.28) EPS. As a group, equities research analysts predict that Aspira Women’s Health will post -1.26 EPS for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 179,371 shares of the company’s stock after buying an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.73% of Aspira Women’s Health worth $732,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.